Daiichi Sankyo & AstraZeneca’s Enhertu receives 2024 Prix Galien USA Award for Best Biotechnology Product: Tokyo Monday, November 11, 2024, 09:00 Hrs [IST] Daiichi Sankyo and As ...

ALT-B4 is Alteogen's proprietary human recombinant hyaluronidase enzyme developed utilizing HybrozymeTM technology. ALT-B4 can enable the large volume subcutaneous administration of drugs that are ...

Alteogen Inc. said that it has entered into an exclusive license agreement with Daiichi Sankyo (DSKYF.PK). As per the terms of the ...

The two companies will use ALT-B4 to develop a subcutaneous version of the antibody-drug conjugate (ADC) cancer treatment ...

Plus, news about Disc Medicine, AlloVir, Kalaris, Travere Therapeutics and Trevena: Daiichi Sankyo, Alteogen to develop subcutaneous version of Enhertu: Daiichi will pay $20 million upfront to the ...

A subcutaneous version of Daiichi Sankyo’s AstraZeneca-partnered blockbuster antibody-drug conjugate (ADC) Enhertu could be ...

While it remains unclear why AstraZeneca China President Leon Wang has been detained, news of his arrest comes just days ...

Winners received prestigious award in recognition of latest innovations in advancement in life sciences ...

Zenvia Inc. (the "Company"), the leading cloud-based CX platform in Latin America, empowering companies to transform their customer journeys, today announced that its fiscal 2024 third quarter and ...

ENHERTU is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo and being ...

Daiichi Sankyo has signed a deal worth up to $300 million with South Korean biotech Alteogen to develop a subcutaneous ...